Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 18, 2007Journal of NeurochemistryOpen Access

The GSK3 hypothesis of Alzheimer’s disease

View Full Paper
Ask AI
Bookmark
Share

Authors

CHClaudie HooperUniversité Toulouse III - Paul SabatierRKRichard KillickKing's College LondonSimon LovestoneSimon LovestoneAstraZeneca (United Kingdom)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hooper et al. (2007) studied this question.

synapsesocial.com/papers/69dee1f05e217d93a5558debhttps://doi.org/10.1111/j.1471-4159.2007.05194.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Wnt signalling pathway2002 · 538 citations
  2. 2Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain1997 · 379 citations
  3. 3Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation2007 · 345 citations
  4. 4Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration2007 · 403 citations
  5. 5Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation2007 · 290 citations